Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

May 2018 - FRMC

Column

Viewpoint
05/31/2018

Virginia Gurley, MD, MPH, Chief Medical Officer at AxisPoint Health

Virginia Gurley, MD, MPH, Chief Medic...
Recognizing the importance of social determinants of health, many health plans are expanding their care management capabilities to help members overcome nonmedical barriers.
Recognizing the importance of social determinants of health, many health plans are expanding their care management capabilities to help members overcome nonmedical barriers.
Recognizing the importance of...
05/31/2018
First Report Managed Care

Department

Managed Care Q&A
05/31/2018

David Costill

David Costill
An interview with Heather Bonome, PharmD, Director of Pharmacy at URAC.
An interview with Heather Bonome, PharmD, Director of Pharmacy at URAC.
An interview with Heather...
05/31/2018
First Report Managed Care
Conference Insider
05/31/2018
Two presentations at the 2018 American Academy of Neurology Annual Meeting highlighted the benefits of the intravenous migraine treatment eptinezumab.
Two presentations at the 2018 American Academy of Neurology Annual Meeting highlighted the benefits of the intravenous migraine treatment eptinezumab.
Two presentations at the 2018...
05/31/2018
First Report Managed Care
Conference Insider
05/31/2018
A recent study presented at the 2018 American Academy of Neurology Annual Meeting found that Aimovig (erenumab; Novartis/Amgen) significantly reduced monthly migraine days among patients who failed two to four prior preventive migraine...
A recent study presented at the 2018 American Academy of Neurology Annual Meeting found that Aimovig (erenumab; Novartis/Amgen) significantly reduced monthly migraine days among patients who failed two to four prior preventive migraine...
A recent study presented at the...
05/31/2018
First Report Managed Care
Conference Insider
05/31/2018
Data presented at the AMCP 2018 Annual Meeting demonstrated that Entresto (sacubitril/valsartan; Novartis) reduced all-cause hospitalizations and health care costs in patients with heart failure with reduced ejection fraction.
Data presented at the AMCP 2018 Annual Meeting demonstrated that Entresto (sacubitril/valsartan; Novartis) reduced all-cause hospitalizations and health care costs in patients with heart failure with reduced ejection fraction.
Data presented at the AMCP 2018...
05/31/2018
First Report Managed Care
Conference Insider
05/31/2018
A study at the AMCP 2018 Annual Meeting compared health care utilization, medication switching, and costs among patients taking oral immunotherapies and injectable immunotherapies.
A study at the AMCP 2018 Annual Meeting compared health care utilization, medication switching, and costs among patients taking oral immunotherapies and injectable immunotherapies.
A study at the AMCP 2018 Annual...
05/31/2018
First Report Managed Care
Conference Insider
05/31/2018
Research presented at the AMCP 2018 Annual Meeting found that Shingrix (non-live adjuvanted subunit vaccine; GlaxosmithKline) is cost-effective when compared with no vaccination and cost-saving compared with an older shingles vaccine.
Research presented at the AMCP 2018 Annual Meeting found that Shingrix (non-live adjuvanted subunit vaccine; GlaxosmithKline) is cost-effective when compared with no vaccination and cost-saving compared with an older shingles vaccine.
Research presented at the AMCP...
05/31/2018
First Report Managed Care
Conference Insider
05/31/2018
A poster presented at the AMCP 2018 Annual Meeting showed that patients with hereditary angioedema who received Haegarda (C1 esterase inhibitor subcutaneous; CSL Behring) took less on-demand therapy during prophylactic treatment.
A poster presented at the AMCP 2018 Annual Meeting showed that patients with hereditary angioedema who received Haegarda (C1 esterase inhibitor subcutaneous; CSL Behring) took less on-demand therapy during prophylactic treatment.
A poster presented at the AMCP...
05/31/2018
First Report Managed Care
Conference Insider
05/31/2018
An award-winning poster at the AMCP 2018 Annual Meeting found that type 2 diabetes patients who need multiple daily injections of basal-bosul insulin have low 1-year persistence and higher medial costs
An award-winning poster at the AMCP 2018 Annual Meeting found that type 2 diabetes patients who need multiple daily injections of basal-bosul insulin have low 1-year persistence and higher medial costs
An award-winning poster at the...
05/31/2018
First Report Managed Care
Conference Insider
05/31/2018
During his presentation at the AMCP 2018 Annual Meeting, “2017-2018 Pharmaceutical Marketplace Trends,” Douglas Long, BS, MBA, vice president of Industry Relations at IQVIA, outlined the market trends impacting the pharmaceutical...
During his presentation at the AMCP 2018 Annual Meeting, “2017-2018 Pharmaceutical Marketplace Trends,” Douglas Long, BS, MBA, vice president of Industry Relations at IQVIA, outlined the market trends impacting the pharmaceutical...
During his presentation at the...
05/31/2018
First Report Managed Care

Advertisement

Advertisement

Advertisement